According to the latest report by IMARC Group, titled, “United States Idiopathic Pulmonary Fibrosis Treatment Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027“, The United States idiopathic pulmonary fibrosis treatment market is expected to exhibit a CAGR of 7.30% during 2022-2027.
Idiopathic pulmonary fibrosis (IPF) refers to an interstitial lung disease that causes a buildup of scar tissues in the lungs. It is diagnosed via blood tests, chest imaging studies, lung biopsies, computer tomography (CT) scans, pulmonary function tests, antibody tests, etc. Idiopathic pulmonary fibrosis is treated by prescribing anti-fibrotic drugs containing nintedanib and pirfenidone salts which aid in minimizing the risk of acute respiratory deterioration. In line with this, several supportive treatment options, such as oxygen therapy, pulmonary rehabilitation, palliative care, etc., are also utilized to provide comfort and improve the recovery of patients.
Get a PDF Sample for more detailed market insights: www.imarcgroup.com/united-states-idiopathic-pulmonary-fibrosis-treatment-market/requestsample
The increasing prevalence of fibrotic diseases, particularly among the geriatric population, on account of the elevating levels of environmental pollutants, is primarily driving the United States idiopathic pulmonary fibrosis treatment market. Moreover, the widespread adoption of nicotine-based items, including cigarettes, is further catalyzing the market growth. Apart from this, the rising consumer awareness towards the availability of effective strategies for preventing and managing IPF is acting as another significant growth-inducing factor. Additionally, numerous technological advancements in diagnostic techniques and extensive improvements in existing healthcare systems are augmenting the market growth in this country. Besides this, the growing investments in R&D activities aimed at developing and commercializing novel drugs are anticipated to fuel the United States idiopathic pulmonary fibrosis treatment market over the forecasted period.
Note: We are regularly tracking the direct effect of COVID-19 on the market, along with the indirect influence of associated industries. These observations will be integrated into the report.
- The competitive landscape of the industry has also been examined along with the profiles of the key players.
The report has segmented the market based on drug class and end user.
Breakup by Drug Class:
- MAPK Inhibitors
- Tyrosine Inhibitors
- Autotaxin Inhibitors
Breakup by End User:
- Long-term Care Facilities
Breakup by Region:
Browse Other Reports by IMARC Group:
GCC Idiopathic Pulmonary Fibrosis Treatment Market Research Report 2022-2027
India Health and Wellness Market Growth, Size, Share, Trends and Forecast 2022-2027
GCC Soft Skills Training Market Trends, Growth, Size, Share and Forecast 2022-2027
Japan Casein Market Share, Industry Report, Trends, Growth, Size and Forecast 2022-2027
GCC Casein Market Share, Industry Report, Size, Trends, Growth and Forecast 2022-2027
Europe Calcium Chloride Market Share, Growth, Size, Trends and Forecast 2022-2027
Europe Idiopathic Pulmonary Fibrosis Treatment Market Share, Trends, Size and Forecast 2022-2027
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
30 N Gould St, Ste R
Sheridan, WY (Wyoming) 82801 USA
Email: [email protected]
Tel No:(D) +91 120 433 0800
Americas: – +1 631 791 1145 | Africa and Europe: – +44-702-409-7331 | Asia: +91-120-433-0800